Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

Bryant, C; Suen, H; Brown, R; Yang, S; Favaloro, J; Aklilu, E; Gibson, J; Ho, P; Iland, H; Fromm, P; Woodland, N; Nassif, N; Hart, D; Joshua, D

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

Bryant, C Suen, H Brown, R Yang, S Favaloro, J Aklilu, E Gibson, J Ho, P Iland, H Fromm, P Woodland, N Nassif, N Hart, D Joshua, D

Permalink

Publisher:: Nature Publishing Group
Publication Type:: Journal Article
Citation:: Bryant, C et al. 2013, 'Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance', Blood Cancer Journal, vol. 3, no. 1, pp. e148-1-e148-7.
Issue Date:: 2013

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download 2013001042OK.pdfAdobe PDF (2.02 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Bryant, C	en_US
dc.contributor.author	Suen, H	en_US
dc.contributor.author	Brown, R	en_US
dc.contributor.author	Yang, S	en_US
dc.contributor.author	Favaloro, J	en_US
dc.contributor.author	Aklilu, E	en_US
dc.contributor.author	Gibson, J	en_US
dc.contributor.author	Ho, P	en_US
dc.contributor.author	Iland, H	en_US
dc.contributor.author	Fromm, P	en_US
dc.contributor.author	Woodland, N	en_US
dc.contributor.author	Nassif, N	en_US
dc.contributor.author	Hart, D	en_US
dc.contributor.author	Joshua, D	en_US
dc.date.accessioned	2014-04-14T02:54:29Z
dc.date.available	2014-04-14T02:54:29Z
dc.date.issued	2013	en_US
dc.identifier	2013001042	en_US
dc.identifier.citation	Bryant, C et al. 2013, 'Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance', Blood Cancer Journal, vol. 3, no. 1, pp. e148-1-e148-7.	en_US
dc.identifier.issn	2044-5385	en_US
dc.identifier.other	C1	en_US
dc.identifier.uri	http://hdl.handle.net/10453/27296
dc.description.abstract	Despite improved outcomes in multiple myeloma (MM), a cure remains elusive. However, even before the current therapeutic era, 5% of patients survived >10 years and we propose that immune factors contribute to this longer survival. We identified patients	en_US
dc.publisher	Nature Publishing Group	en_US
dc.relation.ispartof	Verified OK	en_US
dc.relation.ispartof	Blood Cancer Journal	en_US
dc.relation.isbasedon	http://dx.doi.org/10.1038/bcj.2013.34	en_US
dc.subject	Immature Dendritic Cells; Bone-Marrow; 10-Year Survival; Disease Burden; Therapy; Thalidomide; Expansions; Frequency; Transplantation; Lymphocytes	en_US
dc.subject.classification	Clinical Sciences	en_US
dc.title	Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance	en_US
dc.type	Journal article
utslib.citation.volume	3	en_US
utslib.citation.number	1	en_US
utslib.location	London	en_US
utslib.citation.startpage	e148-1	en_US
utslib.citation.endpage	e148-7	en_US
utslib.identifier.org	SCI.Faculty of Science	en_US
utslib.for	110300	en_US
utslib.percentage	100	en_US
utslib.copyright.status	open_access

Abstract:

Despite improved outcomes in multiple myeloma (MM), a cure remains elusive. However, even before the current therapeutic era, 5% of patients survived >10 years and we propose that immune factors contribute to this longer survival. We identified patients

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/27296